NCT05909995 is a Phase 1 clinical trial of INCB 99280 with Ipilimumab in Melanoma, sponsored by Incyte Corporation.

Who is sponsoring NCT05909995?

NCT05909995 is sponsored by Incyte Corporation.

What drugs are being tested in NCT05909995?

Interventions in NCT05909995: INCB 99280 with Ipilimumab.

What condition does NCT05909995 study?

NCT05909995 studies Melanoma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC), Microsatellite Instability - High (MSI-H), Mismatch Repair Deficient (dMMR), Colorectal Carcinoma (CRC).

Is NCT05909995 still recruiting?

NCT05909995 is currently terminated. Last updated 18 February 2025.

Last reviewed 2025-02-18 · How we verify

NCT05909995

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

Terminated Phase 1 Last updated 18 February 2025

What this trial tests

Phase 1 trial testing INCB 99280 with Ipilimumab in Melanoma in 8 participants. Terminated before completion.

Timeline

29 August 2023

Primary endpoint
19 September 2024

11 November 2024

Quick facts

Lead sponsor	Incyte Corporation
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	29 August 2023
Primary completion	19 September 2024
Estimated completion	11 November 2024
Sites	8 locations across South Africa, Canada, United States

Drugs / interventions tested

INCB 99280 with Ipilimumab — full drug profile →

Conditions studied

Melanoma — all drugs for Melanoma →
Hepatocellular Carcinoma (HCC) — all drugs for Hepatocellular Carcinoma (HCC) →
Renal Cell Carcinoma (RCC) — all drugs for Renal Cell Carcinoma (RCC) →
Microsatellite Instability - High (MSI-H) — all drugs for Microsatellite Instability - High (MSI-H) →

Sponsor

Incyte Corporation — full company profile →

Who can join

18 and older, any sex, with Melanoma or Hepatocellular Carcinoma (HCC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants with select solid tumors.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Emerging strategies in colorectal cancer immunotherapy: enhancing efficacy and survival.
Zhang Y, Guan H, Feng X, Liu M, et al · · 2025 · cited 1× · PMID 41112277 · DOI 10.3389/fimmu.2025.1616414

Verify or expand the search:

Other recruiting trials for Melanoma

Currently open trials in the same condition.

NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07224425 — A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it · Phase 1 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT07225036 — Promoting Immunotherapy Efficacy With Low-Dose Liver RT · NA · recruiting
NCT07379138 — Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improve · NA · recruiting

Other Incyte Corporation trials

Trials by the same sponsor.

NCT07124078 — A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Di · Phase 2 · recruiting
NCT07441694 — Study of INCA036978 in Participants With Myeloproliferative Neoplasms · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting
NCT07284849 — A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 i · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05909995 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Incyte Corporation
Last refreshed: 18 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05909995.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing